Mirabilis Medica, the Bothell, WA-based developer of ultrasound technology to treat uterine fibroids, has raised $1 million in debt and options out of a financing round that could be worth $2 million, according to a regulatory filing. This company, which Xconomy profiled last June, said last year it had raised $11 million since inception from backers that include Charter Life Sciences, vSpring Capital, Arboretum Ventures, Split Rock Partners, and Dow Chemical.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
